311 related articles for article (PubMed ID: 24647572)
41. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.
Hubensack M; Müller C; Höcherl P; Fellner S; Spruss T; Bernhardt G; Buschauer A
J Cancer Res Clin Oncol; 2008 May; 134(5):597-607. PubMed ID: 17932689
[TBL] [Abstract][Full Text] [Related]
42. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Bleau AM; Hambardzumyan D; Ozawa T; Fomchenko EI; Huse JT; Brennan CW; Holland EC
Cell Stem Cell; 2009 Mar; 4(3):226-35. PubMed ID: 19265662
[TBL] [Abstract][Full Text] [Related]
43. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
[TBL] [Abstract][Full Text] [Related]
44. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
[TBL] [Abstract][Full Text] [Related]
45. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
[TBL] [Abstract][Full Text] [Related]
46. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
47. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract][Full Text] [Related]
48. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O
Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484
[TBL] [Abstract][Full Text] [Related]
49. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
50. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
[TBL] [Abstract][Full Text] [Related]
51. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
[TBL] [Abstract][Full Text] [Related]
52. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
Wang L; Leggas M; Goswami M; Empey PE; McNamara PJ
Drug Metab Dispos; 2008 Dec; 36(12):2591-6. PubMed ID: 18799806
[TBL] [Abstract][Full Text] [Related]
53. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Agarwal S; Elmquist WF
Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
[TBL] [Abstract][Full Text] [Related]
54. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
[TBL] [Abstract][Full Text] [Related]
55. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
[TBL] [Abstract][Full Text] [Related]
56. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
Song YK; Kim MJ; Kim MS; Lee JH; Chung SJ; Song JS; Chae YJ; Lee KR
Eur J Pharm Sci; 2022 Jun; 173():106177. PubMed ID: 35341895
[TBL] [Abstract][Full Text] [Related]
57. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Barazzuol L; Jena R; Burnet NG; Meira LB; Jeynes JC; Kirkby KJ; Kirkby NF
Radiat Oncol; 2013 Mar; 8():65. PubMed ID: 23510353
[TBL] [Abstract][Full Text] [Related]
59. Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Vautier S; Milane A; Fernandez C; Chacun H; Lacomblez L; Farinotti R
J Pharm Pharm Sci; 2009; 12(2):199-208. PubMed ID: 19732497
[TBL] [Abstract][Full Text] [Related]
60. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
F Martins ML; Loos NHC; Mucuk S; de Jong D; Lebre MC; Rosing H; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2021 Dec; 18(12):4371-4384. PubMed ID: 34730366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]